Myriad Genetics
MYGN
227 hedge funds and large institutions have $2.15B invested in Myriad Genetics in 2019 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 78 increasing their positions, 73 reducing their positions, and 19 closing their positions.
58% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 19
3% more funds holding
Funds holding: 221 → 227 (+6)
1.03% more ownership
Funds ownership: 105.3% → 106.32% (+1%)
7% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 73
3% less capital invested
Capital invested by funds: $2.23B → $2.15B (-$73.6M)
37% less call options, than puts
Call options by funds: $8.74M | Put options by funds: $13.9M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$71.9M |
| 2 |
Morgan Stanley
New York
|
+$31.3M |
| 3 |
Millennium Management
New York
|
+$20.3M |
| 4 |
D.E. Shaw & Co
New York
|
+$10M |
| 5 |
Barclays
London,
United Kingdom
|
+$8.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$35.2M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$34.2M |
| 3 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$13.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9.07M |
| 5 |
BAMCO Inc
New York
|
-$8.16M |
MYGN Hedge Fund Activity: Q4 2019 in Review
227 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q4 2019, worth a combined $2.15B — down 3.3% from $2.23B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new MYGN positions and 19 closed out — a net gain of 11 holders — while 78 added to existing stakes and 73 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $71.9M. The largest seller was Invesco, cutting an estimated $35.2M.
- 227 institutional investors held Myriad Genetics (MYGN) as of Q4 2019, up from 221 in Q3 2019.
- Funds reported $2.15B of Myriad Genetics stock for Q4 2019, down 3.3% quarter-over-quarter.
- 30 funds opened new Myriad Genetics positions in Q4 2019 and 19 closed out, a net change of +11 holders.
- The largest Myriad Genetics buyer in Q4 2019 was Deutsche Bank, an estimated $71.9M added.
- The largest Myriad Genetics seller in Q4 2019 was Invesco, an estimated $35.2M sold.
Based on aggregated 13F filings for Q4 2019.